Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

Determining the Management and Quality of Life of Patients with Pituitary Tumours.

[1]Dr. Narasingha Pradhan, [2]Dr. Rabinarayan Panda, [3]Dr. Sudhanshu Sekhar Mishra, [4]Dr. Deepak Kumar Das.

[1]Post Graduate Student, Neurosurgery, SCB Medical College & Hospital, Cuttack, Odisha

[2]Assistant Professor, Neurosurgery, SCB Medical College & Hospital, Cuttack, Odisha

[3]Professor, Neurosurgery, SCB Medical College & Hospital, Cuttack, Odisha

[4]Assistant Professor, Neurosurgery, SCB Medical College & Hospital, Cuttack, Odisha

(Received: 27 October 2023 Revised: 22 November Accepted: 26 December)

KEYWORDS

Pituitary gland, Lactotropes, Somatotropes, Pituitary adenomas, Parathyroidoids, Microadenomas.

ABSTRACT:

Recent developments in proteomic research on pituitary adenomas (PA) have improved our comprehension of these tumours' hormonal states.

Aim: The researchers set out to learn more about pituitary tumour care and patients' quality of life after treatment.

Materials and methods: The Institutional Review Board approved this study to ensure it followed all applicable ethical guidelines. The location of the present investigation is Cuttack, Odisha. The CB Medical College and Hospital was the site of the operation.

Using a retrospective observational technique, this research assessed patients' quality of life with pituitary tumours and the therapeutic options accessible to them. For the present investigation, twenty-five individuals were a part of the study. The study population consisted of patients diagnosed with pituitary tumours between and. To measure the concentrations of GH, LH, FSH, and TSH, researchers utilized ELISA kits made by MERCK. The procedures were adjusted per the guidelines provided in the kit instructions.

Results: Concerning the current research, a total of twenty-five persons were included in the study that was being conducted. Among them, 23 people, which accounted for 92% of the sample, revealed poor visual acuity. On the other hand, the remaining two individuals, which accounted for 8% of the sample, displayed normal visual acuity. From the investigation's conclusions, it was determined that fundoscopy produced typical results in 44 per cent of the patients who were checked. In 44 per cent of the patients, papilledema was identified; in 12 per cent of the cases, optic atrophy was found. Twelve per cent of the individuals assessed for this research did not undergo perimetry. However, abnormal field defects were identified in twenty per cent of the cases.

In contrast, typical field defects were seen in sixty-eight per cent of the remaining instances. Conclusion: According to the findings of this research, tailored treatment strategies are fundamental to achieving the best possible clinical outcomes and quality of life for patients with pituitary tumours. Based on the study results, suggestions were given for future research, prospective areas of improvement in the care of pituitary tumours, and evaluations of quality of life were carried out. This research aims to enhance patient outcomes and quality of life in general by providing insightful and comprehensive information on the complex elements of the advancements in pituitary tumour treatment strategies.

Introduction:

Located close to the brain's base and deriving from the inferior hypothalamus, the pituitary gland cannot weigh more than 0.5 grams. Because the endocrine gland controls the secretion of vital hormones, the pituitary gland is often called the "master gland" [1]. Hormones control essential physiological functions like metabolism, growth, blood pressure, and reproduction [2]. Three distinct anatomical components make up the pituitary gland: the anterior, middle, and posterior lobes. Hormone synthesis and secretion are the responsibilities

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

of these endocrine cells, encompassing lactotrophs, somatotropes, and corticotropes [4]. Many of these cells make up the frontal lobe. Not only does the hypothalamus secrete hormones, but it also controls their release and synthesis. Adenomas of the pituitary gland have been identified within the anterior lobe of the gland. The third is the responsibility of the posterior lobe, an extension of the hypothalamus, to secrete these hormones into circulation. In contrast, the hypothalamus itself is directly responsible for hormone synthesis.

The term "pituitary adenomas" (PA) refers to neoplasms originating in the pituitary gland and not spreading to other abdominal organs. In times past, personal assistants were classified according to the physical proportions of their bodies. The diameter of microadenomas is little more than 10 millimetres, whereas the remaining portion of the tumour comprises macroadenomas [1-5]. Recent developments in proteomic studies on PAs have improved our knowledge of the many hormonal states presented by these tumours [6]. Based on their capacity to produce hormones, phosphorous is classified as functional or non-functional [7]. Clinical characteristics that are connected with the endocrine system are shown by patients who have been diagnosed with functional PAs. There is a connection between these phenotypes and a variety of symptoms that are associated with hyperpituitarism or hypopituitarism. These symptoms vary according to the hormone secretion levels influenced by PA [8]. Individuals who have non-functional parathyroidoids may not manufacture any visible hormones, yet they continue to be clinically active. These individuals may present with symptoms associated with mass impact, such as headaches and visual impairment [4–6]. As a result of the fact that they do not exhibit any symptoms, one-third of PAs are considered to be "incidentalomas" of the pituitary gland. They are commonly discovered by chance during imaging procedures unrelated to the disease or post-mortem exams [10].

Although there has been continuous improvement in pharmacological and radiotherapeutic therapies for the management of pituitary tumours, surgical surgery is still the preferred method for most cases. This study addressed that gap by investigating pituitary tumour treatment options, patient outcomes, and quality of life.

Materials & methods:

The Institutional Review Board approved the research and carried out in compliance with ethical standards. The location of the present investigation is Cuttack, Odisha. The CB Medical College and Hospital was the site of the operation. Using a retrospective observational technique, this research assessed patients' quality of life with pituitary tumours and the therapeutic options accessible to them. For the present investigation, twenty-five individuals were a part of the study. The study population consisted of patients diagnosed with pituitary tumours between and. We carefully reviewed all participants' medical records to determine if any information was relevant, and they all gave informed consent. All participants' ages, genders, and countries of origin were meticulously recorded. The patient's medical history, including any co-occurring conditions, was documented. We considered the tumour's size, location, and the hormone activity. Imaging investigations and hormone testing are among the established diagnostic procedures. To measure the concentrations of GH, LH, FSH, and TSH, researchers utilized ELISA kits made by MERCK. Following the guidelines in the kit manuals, the procedures were adjusted as needed.

Some acknowledged treatment methods include surgical procedures, radiation therapy, and other pharmacological management strategies. Recordings were made of the time and the sequence of the interventions. Unwanted side effects of treatment and the repercussions of such side effects were found. Pituitary tumours, including adenomas and other histological subtypes, have been diagnosed in patients who have been given a definitive diagnosis- adults who are older than 18 years old. During the research project, the participants who gave their informed permission to participate in the study were referred to as consents and agreements. Medical care records are available: Patients with comprehensive and readily available medical records include documentation of their diagnosis, treatment history, and information on follow-up measures- the incorporation of a diverse patient group in terms of both gender and socioeconomic standing.

The following therapies were administered to patients: surgery (either transsphenoidal surgery or craniotomy)

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

or a combination of these procedures. The treatment of radiation. The use of pharmaceutical hormonal control methods might be considered medical treatment. Patients agreed to undergo a minimum follow-up time of [specified length] to provide an accurate assessment of the treatment results and quality of life. Patients with an adequate level of cognitive ability are capable of taking part in quality-of-life evaluations and providing relevant responses. Those individuals who had not previously participated in comparable research investigated pituitary tumour treatment and quality of life.

Some of the grounds for exclusion were as follows: Patients under 18. Those individuals who do not have a confirmed pituitary tumour diagnosis are considered to have inadequate diagnostic confirmation. Since the participants' medical data were either absent or inaccessible, a comprehensive evaluation of their diagnosis, treatment, and subsequent assessment was impossible. Pregnancy and Lactation: Pregnant or nursing individuals may have difficulty conducting quality-of-life assessments due to the hormonal changes that occur during these times. Patients who suffer from significant comorbidities that might severely affect their quality of life, regardless of whether or not they were diagnosed with pituitary tumours, are considered to have severe comorbidities. Patients were classed as having cognitive impairment if they had a significant amount of cognitive impairment or if they had mental disorders that might potentially affect their ability to participate in quality-of-life questionnaires. Patients who were diagnosed with pituitary tumours with other cancers that were not connected to pituitary tumours were thought to have concurrent cancers. The individuals who were reluctant or unable to offer informed permission to participate in the research are "individuals who were unwilling or unable to provide informed consent.".

Statistical analysis:

Statistical analysis was performed using SPSS and Microsoft Excel 2010 when data collection was finished. The p-value was less than 0.05 when baseline statistics were included in the study.

Results:

Figure 1: Gender distribution in the study population



As shown in Figure 1, the population under investigation consisted of 25 individuals, 17 (68%) male and 8 (32%) female. Frequency distribution of ages was seen in the randomly sampled population, and the mean age was determined to be 45.7 years. This investigation showed that twenty-four individuals, or 96%, reported having headaches. Additionally, forty individuals, which is the majority of the participants, reported experiencing vomiting. Six patients, equivalent to twenty-four per cent of the total sample, reported experiencing a seizure out of the twenty-five patients.

Additionally, as seen in Figure 2, three patients, which accounts for twelve per cent of the total, reported feeling altered sensoria. A total of 25 people participated in the research being conducted here. Among them, 23 people, which accounted for 92% of the sample, revealed poor visual acuity. On the other hand, the remaining two individuals, which accounted for 8% of the sample, displayed normal visual acuity. From the investigation's conclusions, it was determined that fundoscopy produced average results in 44 per cent of the patients who were checked. In 44 per cent of the patients, papilledema was identified; in 12 per cent of the cases, optic atrophy was found. Twelve per cent of the individuals assessed for this research did not undergo perimetry. A total of sixty-eight per cent of the remaining patients had typical field defects. In contrast, twenty per cent of the cases displayed aberrant field defects.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

Figure 2: Distribution of Sensory Modification in the Sample Population



Figure 3: Hormones prevalence in the sample population



In this study, 25 individuals were evaluated for growth hormone (GH) levels; 54 per cent of those patients had normal levels, 44 percent had low levels, and 4 percent had high levels. In this study, abnormal levels of luteinizing hormone (LH) were found in 76% of patients. In contrast, low follicle-stimulating hormone (FSH) levels were found in 24% of instances. Results showed that TSH levels were within the normal range in 68% of patients and significantly low in 32%. According to our findings, 72% of patients had normal prolactin levels, 24% had insufficient, and 4% had high levels (Fig. 3).

RADIOLOGICAL PHOTOGRAPHS OF PITUITARY MACROADENOMA

A.



B.



Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

C.



Photograph 1: MRI showing A. Axial section B. Coronal, section C. Sagittal section, showing expanded sella with irregularly marginated heterogeneously enhancing mass involving the sella, parasellar, and suprasellar extension S/O pituitary macroadenoma with apoplexy.

A.



B.



C.



Photograph 2: MRI showing A. Axial section B. Coronal, section C. Sagittal section, showing pituitary macroadenoma involving sellar, parasellar and suprasellar region, typical "snowman appearance" with B/L Internal Carotid artery encasement.

Data are not shown in tables or figures because of space limitations.

Twenty-five patients displayed suprasellar extension, 20 exhibited parasellar extension, and no intraventricular extension. Hydrocephalus was seen in 56% of the patients who participated in the current study. In contrast, it was not present in 44% of individuals. Out of the twenty-five patients who participated in this trial, twenty-one received subtotal resection, three patients came very near to receiving complete resection, and one patient passed away. It was discovered that in 48 per cent of the patients, post-operative complications were present. These problems included diabetes insipidus, third nerve palsy in eight per cent of the cases, and fatality in one of the cases. Twenty-three of the twenty-five patients who participated in this experiment were followed up three months later. Most patients, or 56%, could recover, as indicated by a Glasgow outcome score of 4. Post-operative radiation was administered to 33.3% of the individuals who participated in these investigations, whereas 66.7% did not get it.

A pituitary adenoma was present in thirteen of the twenty-five individuals who participated in the current investigation. Figure 1 shows that out of the 25 people that made up the research population, 17 (68%) were male, and 8 (32%) were female during the study. It was discovered via the analysis of the frequency distribution of ages for the population under investigation that the average age was 45.7 years. Twenty-four of the patients, or 96%, said that they were suffering from a headache, forty of them, or 24 percent, reported that they had thrown up, six of the twenty-five patients who were having seizures, and three of the twelve patients who had altered sensorium. Two of the twenty-five patients who participated in our research had normal visual acuity, whereas there were twenty-three patients who had impaired eyesight. 44 percent of the patients were found to have papilledema, while 12 percent of the cases had fundoscopy results that were normal. Thirty-two percent of the cases that were investigated in the research did not undergo perimetry; field defects were normal in sixty-eight percent of the cases and abnormal in twenty percent of the cases investigated.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

Discussion:

Within the scope of this investigation, twenty-five individuals with pituitary adenoma were investigated. The male-to-female sex ratio was 2:1, which was higher than the range of 0.8 to 1.46 that was seen in studies that were comparable [11-13]. For comparison, the mean age of the male and female patients in this analysis was 45.5 years, which is somewhat lower than the mean age of patients in another study conducted by Esiri et al. which was conducted by the same researchers. [14] The relatively small sample size is a potential factor that contributes to the proportion of males to females that is slightly higher and the average age of the participants. The mass effect is the third most common manifestation, and it can take place either with or without the presence of concomitant endocrinopathy. Vision impairment and headaches are the most common side effects that can be caused by mass impacts. Through the combination of mass effects and increased intracranial pressure, massive tumors have the ability to bring on migraines. In the event that a little tumor is present, an increase in intrasellar pressure that causes the dural membrane to rupture and activates pain receptors has the potential to bring on migraines. The invasion of the cavernous sinuses and the stimulation of the trigeminal pain pathway are two other possible processes that have been postulated to be responsible for the onset of headaches. In most cases, patients who have been diagnosed with pituitary tumors that are not particularly large do not exhibit any visual problems. On the other hand, if the pituitary tumor has grown to a diameter of more than one centimeter, the individual will have a specific visual impairment that is defined by poor peripheral vision in both eyes. An other noteworthy symptom that may be present is the presence of dual vision. Both optic chiasma and compression of one branch of the optic nerve can lead to vision impairment. Both of these conditions can come about. Pituitary adenoma is characterized by a number of signs and symptoms, the most prevalent of which is visual impairment, as indicated by prior research [10, 15,16]. When compared to the findings of my research, which showed that the vision loss ranged from 53% to 93%, the studies reported a range of vision loss that was 92%. While the proportion of headaches in the previous study ranged from 8–90%, the percentage of headaches in the current trial was 96%. The percentage of intracranial cancers that are caused by pneumonia is roughly ten percent. Among the several types of pituitary tumors, the most common form is pituitary adenomas that do not function [17].

Adenomas of the pituitary gland that are not functioning properly are the result of monster tumors that block the normal pituitary gland. The following hormones are affected by compression in the order of decreasing gonadotropins, such as LH and FSH: prolactin (67 percent), growth hormone (61 percent to 100 percent), gonadotropins (36 to 96 percent), thyroid stimulating hormone (eight to eighty-one percent), and adrenocorticotropic hormone (17 to 62 percent).

In the present investigation, the form of pituitary adenoma that was shown to be the most frequent was the non-functional pituitary adenoma, which was explored by Cozzi et al. [17].

LH>TSH>PROLACTIN and GH>FSH are the hormones that are known to be most closely connected with depression, as indicated by a research that was conducted by Fleseriu and colleagues. It is [18]. GH levels were found to be normal in 56% of the patients in this investigation, whereas they were found to be lowered in 40% of the cases. In 24% of the instances, the levels of FSH and LH were found to be inadequate, but in 76% of the cases, they were found to be normal. 68% of the patients had normal TSH levels, whereas 32% of the cases had low TSH levels. Cortisol levels in the serum were deemed to be normal in 44% of the cases, low in 52% of the cases, and excessive in 4% of the instances. The levels of prolactin were found to be abnormal in 72% of instances, whereas they were found to be low in 24% of cases. There is a temporary manifestation of diabetes insipidus in as many as one-third of patients who are suffering from pituitary dysfunction; the prevalence of permanent posterior pituitary failure is extremely low, ranging from one to three percent of individuals [19-21]. During the course of this research, fifty percent of the patients acquired diabetic insipidus, and a significantly higher percentage of patients underwent TNTS.

In their study, Flitsch et al. [22] defined gross total resection (GTR) as the removal of 95% of the cancerous tissue around the tumor. Alternatively, the purpose of a subtotal resection, also known as a STR, is to

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(1), 851-858 | ISSN:2251-6727

purposefully maintain remaining lesions in order to reduce the risk of problems that are associated with surgery. The residual tumor (STR) is not defined by a certain proportion of the tumor that is still present; nonetheless, a number of studies have suggested that it is roughly 10% [23,24]. We had a near-total resection rate of 12% in our group, whereas the STR rate was 84%.

Conclusion:

If patients with pituitary tumors want the greatest potential clinical results and quality of life, this study's findings suggest that individualized treatment plans are crucial. The study's results informed decisions about where to focus future studies, how to better treat pituitary tumors, and how to measure patients' quality of life. By shedding light on the intricate details of recent developments in pituitary tumor treatment methods, this research aims to improve patient outcomes and overall quality of life.

Conflict of interest:

The authors declare that they have no conflict of interest.

References:

1. Lu L, Wan X, Xu Y, Chen J, Shu K, Lei T. Prognostic factors for recurrence in pituitary adenomas: recent Progress and future directions. Diagnostics. 2022 Apr 13;12(4):977.
2. Guo X, Zhang D, Pang H, Wang Z, Gao L, Wang Y, Ma W, Lian W, Xing B, Xu X, Xue Y. Safety of Withholding Perioperative Hydrocortisone for Patients With Pituitary Adenomas With an Intact Hypothalamus-Pituitary-Adrenal Axis: A Randomized Clinical Trial. JAMA Network Open. 2022 Nov 1;5(11):e2242221-.
3. Carsote M, Nistor C, Stanciu M, Popa FL, Cipaian RC, Popa-Velea O. Neuroendocrine parathyroid tumors: quality of life in patients with primary hyperparathyroidism. Biomedicines. 2023 Jul;11(7):2059.
4. Baker KE, Robbins AC, Wasson RG, McCandless MG, Lirette ST, Kimball RJ, Washington CW, Luzardo GD, Stringer SP, Zachariah MA. Side-firing intraoperative ultrasound applied to resection of pituitary macroadenomas and giant adenomas: A single-center retrospective case-control study. Frontiers in Oncology. 2022 Nov 30;12:1043697.
5. Kilci F, Jones JH, Çaklılı M, Ceylan S, Çizmecioğlu-Jones FM. Clinical and therapeutic outcomes of pediatric pituitary adenomas: A single-center experience. Endocrine. 2023 Oct 2:1-1.
6. Obel M, Nowicka E, Dzikowski P, Pietrzak Z, Stefaniak M, Obel E. Complex treatment of invasive corticotropic pituitary macroadenoma-Case report. Journal of Education, Health and Sports. 2022 Jul 4;12(7):347-56.
7. Xiao D, Zhang S, Lin K, Zhao L, Wei L, Wang S. Pre-and Post-operative Magnetic Resonance Imaging Comparative Studies of Pituitary Tissues Following Transsphenoidal Resection of Pituitary Macroadenomas. Journal of Integrative Neuroscience. 2023 Aug 4;22(5):107.
8. Ugga L, Franca RA, Scaravilli A, Solari D, Cocozza S, Tortora F, Cavallo LM, De Caro MD, Elefante A. Neoplasms and tumor-like lesions of the sellar region: imaging findings with correlation to pathology and 2021 WHO classification. Neuroradiology. 2023 Apr;65(4):675-99.
9. Hug NF, Purger DA, Moss HE, Dodd RL. Pituitary macroadenoma causing vision loss in Wyburn-Mason syndrome: illustrative case. Journal of Neurosurgery: Case Lessons. 2022 Dec 26;4(26).
10. Kankane VK, Agrawal H, Iyenger SN. Clinico-radiological factors affecting visual recovery in pituitary tumours. Romanian Neurosurgery. 2022 Jun 20:168-74.
11. Karavitaki N, Wass JA. Nonfunctioning and Gonadotrophin-Secreting Adenomas. InThe Pituitary 2022 Jan 1 (pp. 599-613). Academic Press.
12. Jameson JL, Klibanski A, Black PM, Zervas NT, Lindell CM, Hsu DW, Ridgway EC, Habener JF. Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary

adenomas. The Journal of clinical investigation. 1987 Nov 1;80(5):1472-8.
13. Black PM, Hsu DW, Klibanski A, Kliman B, Jameson JL, Ridgway EC, Hedley-Whyte ET, Zervas NT. Hormone production in clinically nonfunctioning pituitary adenomas. Journal of Neurosurgery. 1987 Feb 1;66(2):244-50.
14. Esiri MM, Adams CB, Burke C, Underdown R. Pituitary adenomas: immunohistology and ultrastructural analysis of 118 tumors. Acta neuropathologica. 1983 Mar;62:1-4.
15. Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: A review. Jama. 2023 Apr 25;329(16):1386-98.
16. Rutland JW, Dullea JT, Oermann EK, Feng R, Villavisanis DF, Gilja S, Shuman W, Lander T, Govindaraj S, Iloreta Jr AM, Chelnis J. Post-operative vision loss: analysis of 587 patients undergoing endoscopic surgery for pituitary macroadenoma. British Journal of Neurosurgery. 2022 Jul 4;36(4):494-500.
17. Cozzi R, Lasio G, Cardia A, Felisati G, Montini M, Attanasio R. Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas. Journal of endocrinological investigation. 2009 May;32:460-4.
18. Fleseriu M, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G. Congress of neurological surgeons systematic review and evidence-based guideline for pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery. 2016 Oct 1;79(4):E527-9.
19. Nomikos P, Ladar C, Fahlbusch R, Buchfelder M. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas–a study on 721 patients. Acta neurochirurgica. 2004 Jan;146:27-35.
20. Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, Wang C, Swerdloff RS, Kelly DF. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008 Oct 1;63(4):709-19.
21. Nemergut EC, Zuo Z, Jane JA, Laws ER. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. Journal of neurosurgery. 2005 Sep 1;103(3):448-54.
22. Semple PL, Vance ML, Findling J, Laws Jr ER. Transsphenoidal surgery for Cushing's disease: outcome in patients with a normal magnetic resonance imaging scan. Neurosurgery. 2000 Mar 1;46(3):553-9.
23. Losa M, Picozzi P, Redaelli MG, Laurenzi A, Mortini P. Pituitary radiotherapy for Cushing's disease. Neuroendocrinology. 2010 Sep 1;92(Suppl. 1):107-10.
24. Estrada J, Boronat M, Mielgo M, Magallón R, Millán I, Díez S, Lucas T, Barceló B. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. New England Journal of Medicine. 1997 Jan 16;336(3):172-7.